• 1. An insight into the role of side chains in the microstructure and carrier mobility of high-performance conjugated polymers?
  Jianyao Huang,Dong Gao,Zhihui Chen,Weifeng Zhang Polym. Chem., 2021,12, 2471-2480
• 2. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 3. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 4. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 5. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554

Recent Advances in the Application of 3,5-Difluoropiperidine (CAS: 1228631-14-8) in Chemical Biology and Pharmaceutical Research

3,5-Difluoropiperidine (CAS: 1228631-14-8) has emerged as a critical building block in medicinal chemistry and drug discovery due to its unique structural and electronic properties. Recent studies have highlighted its role as a versatile scaffold for the synthesis of bioactive molecules, particularly in the development of kinase inhibitors and GPCR-targeted therapeutics. This research briefing provides an overview of the latest advancements in the application of 3,5-Difluoropiperidine, focusing on its synthetic utility, pharmacological relevance, and potential therapeutic applications.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of 3,5-Difluoropiperidine derivatives as selective inhibitors of PI3Kδ, a key kinase implicated in inflammatory diseases and cancer. The researchers utilized a structure-based drug design approach, incorporating the 3,5-Difluoropiperidine moiety to optimize binding affinity and selectivity. The lead compound, featuring the CAS: 1228631-14-8 scaffold, exhibited nanomolar potency against PI3Kδ with minimal off-target effects, suggesting its potential as a next-generation anti-inflammatory agent.

In the field of central nervous system (CNS) drug discovery, 3,5-Difluoropiperidine has gained attention for its ability to modulate neurotransmitter receptors. A recent Nature Communications paper reported the development of novel sigma-1 receptor ligands incorporating this scaffold. The fluorinated piperidine ring was found to enhance blood-brain barrier penetration while maintaining high receptor binding affinity. Molecular dynamics simulations revealed that the 3,5-difluoro substitution pattern (CAS: 1228631-14-8) contributes to optimal receptor-ligand interactions, providing insights for future neurotherapeutic development.

The synthetic chemistry of 3,5-Difluoropiperidine has also seen significant advancements. A 2024 ACS Catalysis publication described an innovative asymmetric synthesis route for CAS: 1228631-14-8 using chiral organocatalysis. This method achieved excellent enantioselectivity (>99% ee) and high yield (85%), addressing previous challenges in obtaining optically pure 3,5-Difluoropiperidine derivatives. The developed protocol is particularly valuable for pharmaceutical applications where stereochemistry plays a crucial role in biological activity.

From a drug metabolism perspective, recent pharmacokinetic studies have shown that the 3,5-Difluoropiperidine scaffold (CAS: 1228631-14-8) exhibits favorable metabolic stability compared to its non-fluorinated counterpart. Research published in Drug Metabolism and Disposition demonstrated reduced cytochrome P450-mediated oxidation, leading to improved half-life in preclinical models. These findings support the growing preference for fluorinated piperidines in lead optimization programs across the pharmaceutical industry.

Looking forward, the unique properties of 3,5-Difluoropiperidine (CAS: 1228631-14-8) continue to inspire novel applications. Ongoing research explores its incorporation into PROTACs (proteolysis targeting chimeras) and other targeted protein degradation platforms. The fluorine atoms' electron-withdrawing effects and the ring's conformational flexibility make this scaffold particularly suitable for designing bifunctional molecules in emerging therapeutic modalities.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)